Long-Haul COVID-19 May Affect 2 of 3 With Mild, Moderate Disease
The majority of individuals who experience mild or moderate COVID-19 infection have persistent symptoms more than 30 days after diagnosis.
The majority of individuals who experience mild or moderate COVID-19 infection have persistent symptoms more than 30 days after diagnosis.
A decision on booster shots for the approximately 13.8 million Americans who received the Johnson & Johnson single-shot COVID-19 vaccine is likely to take weeks.
Vaccination protects against SARS-CoV-2 infection and hospitalization during a period with increasing predominance of the delta variant.
The vaccine effectiveness against SARS-CoV-2 infection decreased to 66 percent when the delta variant became predominant.
Study investigators assessed whether the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine is associated with greater risk of peripheral facial nerve palsy.
The approval is indicated for individuals 16 years of age and older, however the vaccine remains available to those aged 12 years and older under the EUA.
The early COVID-19 vaccination campaign in the United States resulted in almost 140,000 averted COVID-19 deaths as of May 9, 2021.
The American College of Obstetricians and Gynecologists (ACOG) strongly recommends that all eligible individuals, including those who are pregnant, recently pregnant, and lactating, receive a COVID-19 vaccine.
Currently available vaccines are effective for preventing SARS-CoV-2 infection and COVID-19-associated hospitalization.
Following implementation of COVID-19 restrictions in Australia in April 2020, there was a reduction in antibiotic dispensing.